 |
TREATMENTS IN THE PIPELINE: 150 headlines |
|
|||||
My Educational Video on MS and MS Trials| Visitors Since 03/2006 |
||||||||||||||||||||||||||||||||||||||
| Our 670 MySpace Friends The New Face of MS |
||||||||||||||||||||||||||||||||||||||
 |
||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||
 Click to view 1280 MS Walk photos! | ||||||||||||||||||||||||||||||||||||||
| "Join a trial at Barrow & receive all medication & study based procedures at no charge!" | ||||||||||||||||||||||||||||||||||||||
Stan Swartz, CEO, The MD Health Channel "WE PRODUCED THE FOLLOWING 9 VIDEOS FOR YOU!" Simply click the "video" buttons below: . |
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| Previious Posts | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
| MS NEWS ARCHIVES: by week | ||||||||||||||||||||||||||||||||||||||
| June 2006 | ||||||||||||||||||||||||||||||||||||||
| July 2006 | ||||||||||||||||||||||||||||||||||||||
| August 2006 | ||||||||||||||||||||||||||||||||||||||
| September 2006 | ||||||||||||||||||||||||||||||||||||||
| October 2006 | ||||||||||||||||||||||||||||||||||||||
| November 2006 | ||||||||||||||||||||||||||||||||||||||
Monday
BIOGEN NOW HAS 5 MS DRUGS: Adding a fifth product to its portfolio of approved and investigational MS therapies...Biogen is 'hoping to offer MS patients a portfolio of potential therapies.'"(CLICK FOR MORE)
Biogen markets two approved MS therapies:
Biogen's development pipeline for MS includes:
Biogen markets two approved MS therapies:
- Avonex, a once-weekly interferon beta-1a injection, pulled in revenues of $429 million for the second quarter
- Tysabri (natalizumab), an alpha-4 antagonist administered by infusion, was voluntarily pulled from the market by Biogen and partner, Dublin, Ireland-based Elan Corp. plc, last year after being linked to a fatal brain infection, but gained a second approval in June in a limited capacity
Biogen's development pipeline for MS includes:
- Rituxan (rituximab), a B-cell targeted therapy that is in Phase II. That product, partnered with South San Francisco-based Genentech Inc., is marketed for rheumatoid arthritis and non-Hodgkin's lymphoma.
- Daclizumab is also in Phase II. Daclizumab, an antibody designed to bind to the IL-2 receptor on activated T cells. Daclizumab was one of three products Biogen licensed from Protein Design Labs Inc., of Fremont, Calif., in an August 2005 deal potentially worth up to $800 million
- Oral CDP323, an oral alpha-4 integrin inhibitor discovered by UCB. A small-molecule prodrug antagonist of alpha-4 integrin, CDP323 has been tested in three Phase I trials in healthy volunteers. Data from those trials was reported last week at the 2006 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Madrid, Spain.